RENAL FUNCTIONAL PARAMETERS UNDER TREATME NT WITH THE ACE-INHIBITOR SPIRAPRIL - CLINICAL-TRIAL IN PATIENTS WITH CHRONIC-RENAL-FAILURE

The objective of this study was to determine the impact on renal funct ion of spirapril, a new ACE inhibitor with a dual elimination pathway. 49 hypertensive subjects (diastolic blood pressure 95 to 115 mmHg) wi th varying degrees of renal insufficiency were treated with 6 mg spira pril once daily. Before and after a 4-week active treatment period ren al function was assessed by Tc-99m-DTPA clearance (congruent to GFR), I-131-hippuran clearance (congruent to RPF) and creatinine clearance ( CLCr). According to the initial CLCr the patients were allocated to gr oups I to III (greater than or equal to 80 ml/min; 30-79 ml/min; <30 m l/min). In 48% of the patients with and 31% of those without renal ins ufficiency, diastolic blood pressure was normalized (less than or equa l to 90 mmHg) or lowered (greater than or equal to 10 mmHg) under spir april treatment. According to the degree of renal failure, GFR, RPF an d CLCr showed significant differences between groups I to m. Spirapril treatment did wt influence renal function. No deterioration was obser ved in GFR, RPF or CLCr in any of the 3 groups.